Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-clivatuzumab tetraxetan in advanced pancreatic cancer
NCT00597129Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2004
- Primary completion
- Oct 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of clivatuzumab tetraxetan in pancreatic adenocarcinoma (PDAC), sponsored by Gilead Sciences. Started Aug 2004; status: completed.
02
Drugs
clivatuzumab tetraxetan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00597129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00597129.